Pharmacist Moms Group^™

A Peterson Health Technology Institute evaluation found virtual chronic kidney disease (CKD) care companies aren’t slowing kidney function decline or boosting medication adherence, despite billions invested.

Romantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.

MRD-guided stopping in multiple myeloma shows many patients stay disease-free for 4 years.

TecDara shows strong myeloma control, but early infection risk demands vigilant prophylaxis; safety improves after six months, supporting second-line use.

New BCMA bispecific shows durable myeloma responses with low severe CRS/ICANS, fewer infections, and convenient outpatient dosing in TRAVINO.

In a Swedish study of 482,000 heart failure hospitalizations, cold effects emerged days later, whereas heat effects appeared almost immediately.

A pharmacy practice professor explains how GLP-1s may blunt reward signaling tied to drinking and why pancreatitis risk belongs in counseling.

Experts from the NEIAP 2026 Annual Forum share how pharmacists are driving hypertension, lipid, cardiorenal, obesity, and CDTM care as primary clinical decision-makers.

Robin Tumlinson, PharmD, BCOP, discusses how biomarker-guided treatment and increasingly complex toxicity profiles are expanding oncology pharmacists’ responsibilities in bladder cancer care.